Special Article

You have free access to this content

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis†

  1. Bevra H. Hahn1,‡,*,
  2. Maureen A. McMahon1,§,
  3. Alan Wilkinson,
  4. W. Dean Wallace1,
  5. David I. Daikh2,
  6. John D. FitzGerald1,
  7. George A. Karpouzas1,
  8. Joan T. Merrill3,‖,
  9. Daniel J. Wallace4,
  10. Jinoos Yazdany2,
  11. Rosalind Ramsey-Goldman5,
  12. Karandeep Singh1,
  13. Mazdak Khalighi1,
  14. Soo-In Choi1,
  15. Maneesh Gogia1,
  16. Suzanne Kafaja1,
  17. Mohammad Kamgar1,
  18. Christine Lau1,
  19. William J. Martin1,
  20. Sefali Parikh1,
  21. Justin Peng1,
  22. Anjay Rastogi1,††,
  23. Weiling Chen1,
  24. Jennifer M. Grossman1

Article first published online: 3 MAY 2012

DOI: 10.1002/acr.21664

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 64, Issue 6, pages 797–808, June 2012

Additional Information

How to Cite

Hahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., Ramsey-Goldman, R., Singh, K., Khalighi, M., Choi, S.-I., Gogia, M., Kafaja, S., Kamgar, M., Lau, C., Martin, W. J., Parikh, S., Peng, J., Rastogi, A., Chen, W. and Grossman, J. M. (2012), American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res, 64: 797–808. doi: 10.1002/acr.21664

Author Information

  1. 1

    University of California, Los Angeles

  2. 2

    University of California, San Francisco

  3. 3

    Oklahoma Medical Research Foundation, Oklahoma City

  4. 4

    Cedars-Sinai Medical Center, University of California, Los Angeles

  5. 5

    Northwestern University, Chicago, Illinois

  1. ‡

    Dr. Hahn has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from UCB and Abbott, and has served on the Data and Safety Monitoring Board for Anthera.

  2. §

    Dr. McMahon has received speaking fees (more than $10,000) from HGS/GSK.

  3. Dr. Wilkinson is deceased.

  4. ‖

    Dr. Merrill has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from UCB, Amgen, Pfizer, Lilly, Bristol-Myers Squibb, Genentech/Roche, EMD Serono, Neovacs, Cephalon, MedImmune, Questcor, Argos, Abbott, Ono, Astellas, Baxter, RPS, and Takeda, and (more than $10,000 each) from Human Genome Sciences/GlaxoSmithKline and Parexel, and has served on the Data and Safety Monitoring Board and/or Adjudication for Industry Trials for Amgen, Celgene, and Pfizer.

  5. ††

    Dr. Rastogi has received consultant fees, speaking fees, and/or honoraria (more than $10,000 each) from ViiV, Novartis, Genzyme, and Cubist.

*University of California, Los Angeles, School of Medicine, Room 32-48 Rehabilitation Building, Box 951670, Los Angeles, CA 90095-1670

  1. †

    Members of the Task Force Panel: Jo H. M. Berden, Jill P. Buyon, Gabriel Contreras, Karen H. Costenbader, Mary Anne Dooley, Peng Thim Fan, Rosalind Ramsey-Goldman, Frederic A. Houssiau, David A. Isenberg, Kenneth C. Kalunian, Susan Manzi, Chi-Chiu Mok, Liz Shaw-Stabler, Brad Rovin, Murray B. Urowitz, and David Wofsy.

  2. ‡

    Dr. Hahn has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from UCB and Abbott, and has served on the Data and Safety Monitoring Board for Anthera.

  3. §

    Dr. McMahon has received speaking fees (more than $10,000) from HGS/GSK.

  4. Dr. Wilkinson is deceased.

  5. ‖

    Dr. Merrill has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from UCB, Amgen, Pfizer, Lilly, Bristol-Myers Squibb, Genentech/Roche, EMD Serono, Neovacs, Cephalon, MedImmune, Questcor, Argos, Abbott, Ono, Astellas, Baxter, RPS, and Takeda, and (more than $10,000 each) from Human Genome Sciences/GlaxoSmithKline and Parexel, and has served on the Data and Safety Monitoring Board and/or Adjudication for Industry Trials for Amgen, Celgene, and Pfizer.

  6. ††

    Dr. Rastogi has received consultant fees, speaking fees, and/or honoraria (more than $10,000 each) from ViiV, Novartis, Genzyme, and Cubist.

Publication History

  1. Issue published online: 3 MAY 2012
  2. Article first published online: 3 MAY 2012
  3. Manuscript Accepted: 5 MAR 2012
  4. Manuscript Received: 15 JUN 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS